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Abstract
There is an urgent need for new drugs against influenza type A and B viruses due to incomplete protection by vaccines and
the emergence of resistance to current antivirals. The influenza virus polymerase complex, consisting of the PB1, PB2 and PA
subunits, represents a promising target for the development of new drugs. We have previously demonstrated the feasibility
of targeting the protein-protein interaction domain between the PB1 and PA subunits of the polymerase complex of
influenza A virus using a small peptide derived from the PA-binding domain of PB1. However, this influenza A virus-derived
peptide did not affect influenza B virus polymerase activity. Here we report that the PA-binding domain of the polymerase
subunit PB1 of influenza A and B viruses is highly conserved and that mutual amino acid exchange shows that they cannot
be functionally exchanged with each other. Based on phylogenetic analysis and a novel biochemical ELISA-based screening
approach, we were able to identify an influenza A-derived peptide with a single influenza B-specific amino acid substitution
which efficiently binds to PA of both virus types. This dual-binding peptide blocked the viral polymerase activity and growth
of both virus types. Our findings provide proof of principle that protein-protein interaction inhibitors can be generated
against influenza A and B viruses. Furthermore, this dual-binding peptide, combined with our novel screening method, is a
promising platform to identify new antiviral lead compounds.
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Introduction
Influenza A and B viruses are closely related RNA viruses,
which cause respiratory disease in humans and other animals.
Both viruses belong to the Orthomyxoviruses, a family of
enveloped, negative-sense RNA viruses that encode their genetic
information in eight segments. While influenza A viruses (FluA)
infect a broad variety of animals as well as humans, influenza B
viruses (FluB) are predominantly found in humans [1]. Recently,
FluA viruses have attracted the world’s attention due to their
ability to cause global pandemics, such as the 1918 ‘‘Spanish’’ flu
or the novel H1N1 influenza virus of swine origin [2,3,4].
However, both FluA and FluB viruses are responsible for seasonal
epidemics, which result in hundreds of thousands of deaths each
year, since FluB can cause the same spectrum of symptoms that is
observed with FluA [5,6,7,8,9]. In most years, only one type causes
the majority of the cases, leading to the exclusion of the others [1].
For this reason, the annual influenza vaccination recommended by
the WHO contains both FluA and FluB strains (http://www.who.
int/csr/disease/influenza/vaccinerecommendations1/en/). Thus,
both types A and B viruses pose a large threat to public health.
Since the current vaccines against influenza viruses offer only
incomplete protection, antivirals are greatly needed. Presently, the
only class of anti-influenza drugs available which are active against
both FluA and FluB are neuraminidase inhibitors oseltamivir
(Tamiflu) and zanamivir (Relenza) [10]. However, many influenza
A strains, including the circulating H1N1 strains in Europe and
the US, are already resistant to oseltamivir [11,12], suggesting a
limited range of use for this type of drug. The resistance is not
restricted to FluA, since the emergence of FluB viruses with
reduced sensitivity to neuraminidase inhibitors is known [13,14].
In addition, the treatment of influenza B, particularly in young
children, is associated with delayed antiviral effects and clinical
resolution [15]. This might be related to the observation that
oseltamivir carboxylate, the active metabolite of oseltamivir, is less
active against the FluB rather than the FluA virus neuraminidase
[13]. Other approved antivirals that target the viral M2 protein,
such as amantadine, are only effective against FluA strains, since
FluB strains lack a comparable M2 protein [16]. Additionally, the
high prevalence of resistance to M2 inhibitors and the general
rapid appearance of resistant strains during treatment restricts the
therapeutic potential of this class of antiviral drugs [17].
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nucleus by the heterotrimeric viral polymerase complex consisting
of the PB1, PB2, and PA subunits. This includes the synthesis of
the genomic RNA from an intermediate copy RNA and the
synthesis of viral mRNA transcripts. Synthesis of the latter
transcripts is dependent on 8–15 nt long primers derived from
the 59ends of capped endogenous mRNAs. PB1 possesses the RNA
polymerization activity, whereas PB2 is known to bind capped
mRNA [18,19,20]. Recently, RNAse activity could be identified in
the N-terminal part of PA, which is most likely necessary to cleave
the primer off the remaining host mRNA [21,22]. The structure of
the trimeric complex at the atomic level is not yet resolved, but
cryo-EM studies do exist [23,24]. Recent crystal structures have
shown that PB1 binds to PA via a 310-helix at its N-terminus
comprised of amino acids (aa) 5–11 [25,26]. This finding is
compatible with previous observations that the PA-binding site is
localized to the extreme N-terminus of PB1 [27,28]. Since the
association of these subunits is essential for viral replication
[28,29,30,31], and since the sequence of this domain of PB1 is
highly conserved among FluA strains [32], this interaction presents
an attractive target for antiviral drugs. We have previously shown
that a peptide derived from the first 25 amino acids of FluA PB1
can inhibit both the polymerase activity and viral spread of FluA
but not FluB [32]. Here, we identify a chimeric FluA/FluB peptide
which is active against both virus types.
Results
The type-specificity of the PA-PB1 interaction is due to
the first 25 amino acids of PB1
Previously, we have shown that the N-terminal 25 aa of FluA
PB1 (PB11–25A) are sufficient to bind FluA-PA and inhibit the
polymerase activity of FluA [32]. However, this sequence was not
able to block the polymerase activity of FluB. Since the first 25 aa
of FluA-PA and FluB-PA differ at 8 positions (Fig. 1A), the failure
to block FluB polymerase activity might be due to impaired
binding of PB11–25A to FluB PA. Alternatively, the PA-binding
domain of FluB PB1 might extend beyond the extreme 25 amino
Figure 1. Virus type-specific conservation of the PA-binding domain and interaction of PA with PB1. (A) Upper panel: Alignment of the
N-terminal 25 aa of FluA and FluB PB1. The dotted box indicates the 310-helix comprising the core PA-binding domain of PB1. FluA-specific (blue) and
FluB-specific (red) aa are highlighted. Middle and lower panels: Alignment of the N-terminal 25 aa of all available FluA and FluB sequences available in
the NCBI influenza virus database. Figures on the right hand side indicate the number of sequences present in the database. Grey bars highlight aa
which reconstitute the 310-helix of FluA PA and possibly of FluB PA. (B) A/SC35M- and B/Yamagata/73-derived PB1 chimeras used in (b). Note that all
PB1 proteins were expressed with C-terminal HA-tags. (C) Human 293T cells were transfected with expression plasmids coding for the indicated PB1
proteins and the C-terminally hexahistidine-tagged PA of FluA (FluA-PAHis). Cell lysates were prepared 24 hours post transfection and subjected to
immunoprecipitation (IP) using anti-HA (aHA) agarose. Precipitated material was separated by SDS-PAGE and analyzed by Western blot for the
presence of either His- or HA-tagged polymerase subunits using appropriate antibodies. Protein expression was controlled by analyzing equal
amounts of cell lysate. Molecular weights are shown in kilodaltons.
doi:10.1371/journal.pone.0007517.g001
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substituting N-terminal regions of varying length from FluA-PB1
into FluB-PB1 (Fig. 1B). After transient co-expression in human
293T cells, we then used immunoprecipitation assays to test which
of these chimeras could bind to FluA-PA. All PB1 chimeras tested,
including a chimera containing only the first 25 aa of FluA-PB1,
could bind FluA-PA equally, whereas wild-type FluB-PB1 could
not (Fig. 1C). This implied that the few aa differences in this small
domain are the major determinant in PB1 for the type-specific
binding of PB1 to PA.
Quantification of the PA/PB1 interaction
To further characterize which amino acid positions are
important for the type-specific binding of PB11–25 to PA, we
developed an ELISA-based binding assay to quantify this
interaction. For this purpose, we immobilized biotinylated
peptides corresponding to PB11–25 on streptavidin-coated plates
and subsequently added cell lysates containing HA-tagged PA.
Bound PA was detected using HA-specific primary and perox-
idase-coupled secondary antibodies. To determine the binding
efficiency of variant peptides we performed the ELISA in a
competitive manner. In this case, non-biotinylated competitor
peptides were added simultaneously with HA-tagged PA to wells
containing immobilized PB11–25 peptide.
The core-binding site of the PA-binding domain of FluA-PB1
was recently determined by co-crystalization with the C-terminus
of PA and is comprised of a 310-helix ranging from aa 5–11 [25].
We therefore first evaluated our FluA-binding assay by using a
soluble wild-type PB11–25A peptide, which resulted in a 50%
inhibitory concentration (IC50) of 1.8 nM (Fig. 2A). A ‘‘scrambled
peptide’’ harboring the same amino acid composition as PB11–25A
but with the order randomized, did not block PA-HA binding at
highest concentrations (3000 nM, data not shown). Next, the
minimal binding domain was determined by deleting aa from the
N- and/or C-terminus of PB11-25A. Determination of the IC50
using the truncated competitor peptides demonstrated that the
3-10 helix is absolutely essential for binding to PA, since any
truncation of this sequence resulted in no competition (Fig. 2B).
This is congruent with the results obtained by mutational analysis
of the PA-binding domain [28]. Residual competition from
partially C- or N-truncated peptides was observed, implying that
some of the aa positions flanking the 3–10 helix may be
dispensable for binding. Specifically, truncating the C-terminal
10 aa of FluA PB11–25A resulted in an IC50 of 43.3 nM compared
to 1.8 nM for the full-length peptide (Fig. 2B). Since this truncated
peptide can efficiently bind to PA, yet still contains many of the
differing aa positions between FluA and FluB, we chose this
sequence as a basis to test variant peptides for their binding to both
FluA- and FluB-PA.
A single amino acid substitution allows PB11-25 to bind
FluA PA and FluB PA
As the PB11–15 sequence differs by 8 aa between FluA and FluB
(Fig. 1A),we decidedto createchimerascontaining combinationsof
FluA- and FluB-specific residues and test these 15mer peptides in
the competitive ELISA using both FluA-PA and FluB-PA. For this
assay, biotinylated PB11–25A was used in combination with FluA-
PA-HA, biotinylated PB11–25B was combined with FluB-PA-HA,
and the competitor peptides were tested with both combinations.
Competitor peptides PB11–15A and PB11–15B, derived from the
wild-type sequences, competed only for FluA PA or FluB PA,
respectively, with no cross-type competition detectable (Fig. 3). We
then tested competitor peptides containing combinations of FluB-
specific aa in the PB11–15A background. While most of these
combinations showed no affinity for FluB, substituting positions 6
and 7 led to a significantly reduced IC50 for FluB-PA as well as a
slight decrease in the IC50 for FluA-PA, suggesting that this peptide
could bind to both proteins. By substituting only the FluB-specific
tyrosine at position 6, efficient binding to PA of both types resulted.
In contrast, changing only position 7 of a FluA- to a FluB-specific
sequence ablated binding to PA of both types. Introduction of a
phenylalanine or tryptophan at position 6 demonstrated that
related residues can significantly increase the binding affinity to
FluA PA, but only partially increase the affinity to FluB PA. A
histidine or cysteine at position 6 led to peptides failing to bind to
FluB PA, while binding to FluAPA was still possible, indicatingthat
not all amino acid substitutions confer the dual-binding activity
observed with tyrosine at this position.
To further confirm that tyrosine at position 6 of FluA PB1 can
bind directly to both FluA- and FluB-PA, we used a biotinylated
25mer peptide PB11–25AT6Y as well as wild-type peptides and cell
lysates containing overexpressed PA-HA derived from several
different FluA and FluB strains in the ELISA. As shown in Fig.
4A–C, PA-HA from several FluA strains of various subtypes,
including a human H5N1 isolate, bound to both PB11–25A and
PB11–25 AT6Y, but not to PB11–25B or a scrambled biotinylated
peptide. Conversely, PA-HA derived from several different FluB
strains bound to both the PB11–25B and PB11–25AT6Y (Fig. 4D).
Thus, a FluA-PB1-derived sequence containing a single substitu-
tion at position 6 can directly bind to PA from different FluA and
FluB viruses. Molecular modeling suggests that the FluB-derived
tyrosine at position 6 of PB11–25AT6Y fits into a hydrophobic
pocket of FluA PA and displaces a water molecule (Fig. 3F). Both
the increased hydrophobic interaction as well as the entropic effect
of the water displacement might explain the enhanced binding of
PB1-T6Y to PA of FluA and possibly of FluB.
PB11–25AT6Y can inhibit the polymerase activity and
spread of FluA and FluB
To demonstrate that PB11–25AT6Y can bind to both FluA- and
FluB-PA in a cellular context, we performed immunoprecipitation
experiments using overexpressed PA and PB11–25 peptides fused to
GFP (Fig. 5B). This confirmed that PB11–25 derived from FluA or
FluB can only bind to FluA-PA or FluB-PA, respectively.
However, PB11–25AT6Y could be immunoprecipitated with either
FluA-PA or FluB-PA.
Next, we tested the ability of these fusion proteins to inhibit the
polymerase activity of both FluA and FluB using a reconstituted viral
ribonucleoprotein complex and a reporter gene. As previously shown
[32], PB11–25A-GFP inhibits the activity of FluA, but not FluB, while
t h ec o n v e r s ei st r u eo fP B 1 1–25B-GFP (Fig. 5C). However,
PB11–25AT6Y-GFP inhibited both FluA and FluB polymerase activity
to comparable levels as the wild-type-derived sequences (Fig. 5C),
indicating that this variant peptide is also biologically active.
Finally, we tested the ability of these peptides to inhibit viral
spread in cell culture. MDCK cells were infected with either A/
WSN/33 (H1N1), A/Thailand/1/2004 (H5N1), B/Yamagata/
73, or vesicular stomatitis virus (VSV) as a specificity control from
a different virus family. A plaque reduction assay was then
performed in the presence of PB11–25A, PB11–25AT6Y,o ra
negative-control peptide fused to an HIV-Tat derived sequence
[33] (Table 1) to allow the peptides to cross the plasma membrane.
Similar experiments with a FluB-derived peptide were not possible
due to its insolubility. The peptide containing the T6Y substitution
inhibited the growth of all influenza strains tested, while PB11–25A-
Tat only inhibited FluA (Fig 6). Thus, a single mutation in the
PB11–25A sequence results in a peptide which is active against both
FluA and FluB strains.
Polymerase Assembly Inhibitor
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7517Figure2.Quantificationofthe interactionbetween PB11–25andPA.(A)Determinationof the50% inhibitory concentration (IC50) ofPB11–25Ab y
competitive ELISA using the indicated increasing concentrations of peptides and cell extract containing HA-tagged PA of FluA. Error bars represent
standard deviations from triplicate experiments. (B) IC50 of PB11–25A-derived peptides. S.D. is shown in parenthesis. Asterisks indicate highest
concentrations of peptides (3000 nM) used without detectable inhibitory effect. Grey boxes highlight amino acids that are part of the 310-helix, which
was postulated to comprise the core PA-binding region of PB1. Amino acids known to form hydrogen bonds with PA residues are represented in bold.
doi:10.1371/journal.pone.0007517.g002
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Here we report that the PA-binding domains of the polymerase
subunits PB1 of influenza A and B viruses are highly conserved
within each virus type, and that these domains are not mutually
exchangeable. Based on phylogenetic analysis and a biochemical
ELISA-based screening approach, we were able to identify a PB1-
derived peptide of influenza A virus with a single influenza B-
specific amino acid substitution which recognizes PA of both virus
types. Significantly, this dual-binding peptide blocked both the
polymerase activity and spread of both viruses and raises the
exciting possibility of developing new antivirals that specifically
interfere with the polymerase complex assembly of both viruses.
The inability of PB11–25A to efficiently bind to FluB-PA and
vice versa strongly indicates that these PA-binding domains show
limited functional compatibility between the two virus types. We
speculate that this incompatibility is caused by an independent
evolution of the FluA and FluB polymerase proteins. This is in
accordance with a virus-type specific conservation of the PA-
binding domain of PB1 (Fig. 1) and further highlighted by an
overall aa identity of the viral polymerase subunits of less than
35% between FluA and FluB strains. Together, these differences
may account for the failure to reconstitute an active trimeric
polymerase complex by mixing FluA and FluB polymerase
subunits ([34,35,36], unpublished results). However, both FluA
and FluB viruses have a common origin [1]. Thus, it is not
unexpected that the aa residues of PA which are in close contact
with PB11–25 are conserved between FluA and FluB [25,26],
indicating that the PA domain of both virus types bind PB1 in a
similar fashion. This similarity might explain how one single
amino acid substitution (T6Y) in PB11–25A is sufficient to allow
binding to FluB-PA. Based on the available crystal structure of PA
complexed with the N-terminus of PB1 and our modeling results
with this dual-binding peptide PB11–25A6Y (Fig. 4F), we speculate
that the tyrosine residue might exploit a hydrophobic pocket in the
PB1-binding domain of FluB PA, thereby stabilizing the
interaction. Such an occupation of a hydrophobic pocket may
also be important to stabilize the interaction between PB11–25A6Y
and FluB PA.
Both the identification of the FluA- and FluB-PA-binding peptide
PB11–25AT6Y and our novel ELISA-based screening assay provide a
unique platform for future screening of small molecules targeting
the PB1/PA interaction of both virus types. Such inhibitors
represent attractive new tools to disrupt a variety of protein-protein
interactions (PPI) [37,38]. Initial attempts to identify PPI inhibitors
were challenged by the large contact surfaces of protein-protein
interfaces. However, the identification of a small subset of aa
residues, such as the PA-binding domain of PB1 that contribute to
most of the free energy of binding provide excellent targets. Recent
screening approaches led to the identification of potent PPI
inhibitors that block dimerization between the human protein
double mutant 2 (HDM2) and a 15-residue a-helical region of the
tumor suppressor p53 [39], the basic helix-loop-helix leucine zipper
(bHLHZip) transcription factor Myc and Max [40] or the
interaction between paxilin and the integrin a4 [41]. Proof-of-
principle that viral protein interactions are also attractive targets for
the generation of PPI inhibitors was first obtained with human
papilloma virus [42] and herpes simplex virus type 1 (HSV-1) [43].
In the case of HSV-1, the interaction between the catalytic subunit
of the HSV-1 polymerase (UL30) and its cofactor, the processivity
factor UL42 was targeted. Similar to the interaction of PB1 and PA,
the extreme 18 C-terminal residues of UL30 are sufficient to bind to
UL42. Using a biochemical screening assay based on the specific
interaction of this C-terminal peptide and UL42, several potent
small molecule inhibitors were identified [43]. It is therefore
reasonable to assume that PPI inhibitors that block the dimerization
of PB1 and PA can also be identified using the newly established
ELISA-based screening assay. Indeed, recent results indicate that
this approach has the potential to identify PPI inhibitors that
prevent viral polymerase activity and replication of both types of
influenzaviruses(Kessleretal.,unpublishedresults).Webelieve that
the PB1/PA interface is an excellent target for PPI inhibitors,
because the PA-binding domain within the extreme N-terminus of
PB1iscrucial fortheinteractionwith PA, sincePB1 mutants lacking
this domain fail to interact with PA [28]. Using PB11–25A6Y and
FluA PA for screening, we expect that some PPI inhibitors possess a
high specificity against both influenza virus types. This is supported
by our observations that PB11–25A6Y blocks the growth of FluA and
FluB but not VSV.
Besides the PA/PB1 complex, other targets of influenza viruses
have become attractive for the development of PPI inhibitors,
including the interaction interface between PB2 and PB1, for which
the crystal structure was recently solved [44]. Additionally, based on
the crystal structure of a fragment of PB2 bound to the cap analog
m7GTP [20], non-PPI inhibitors might become feasible that
compete with cap-binding properties of PB2. Furthermore, the
Figure 3. Binding characteristics of FluA and FluB PB1-derived peptide chimera. Inhibitory concentrations of FluA/FluB-derived peptides
determined by competitive ELISA. Competitor peptides (0.048 to 3000 nM) were mixed with cell extracts containing HA-tagged PA from either FluA
or FluB. Letters in red indicate FluB, letters in blue FluA specific aa. S.D. is indicated in parenthesis. Asterisks indicate highest concentrations of
peptides used without reaching 50% inhibition.
doi:10.1371/journal.pone.0007517.g003
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7517Figure 4. Dual-binding properties of the FluA/B peptide chimera PB11–25AT6Y. (A) – (D) Binding of overexpressed HA-tagged PA subunits of
differing influenza strains in cell extracts to the immobilized peptides corresponding to the domains of FluA PB1 (PB11–25A), FluB PB1 (PB11–25B) or
FluA PB1 T6Y (PB11–25AT6Y) was determined by ELISA. Signals using the cognate peptide and lysate were normalized to 1. Binding of the PA subunits
to the control peptides was not observed (data not shown). Upper panels: Western blot of the PA-containing cell extracts used. Molecular weights
shown in kilodaltons. (F) Structure of FluA PB11–15 (green) bound to FluA PA (grey) as published [25]. T6 forms a hydrogen bond (green line) to a
water molecule (blue). Molecular modeling suggests that the aromatic side chain in the mutant T6Y (orange) fits into a hydrophobic pocket and
displaces the water molecule.
doi:10.1371/journal.pone.0007517.g004
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in the N-terminal domainof PA [21,22] provides a further targetfor
the development of effective inhibitors. However, it has yet to be
shown whether these targets are suitable for the development of
antivirals. Since the available information of these novel targets is
restricted to FluA strains, it remains unclear whether such antivirals
may also be active against FluB.
Attempts to substitute position 6 of the FluA PB11–25A peptides
with other residues than tyrosine did not result in improved FluB-
PA binding in the competitive ELISA experiments. However,
replacements with either phenylalanine or tryptophan residues
enhanced binding to FluA-PA approximately 20 fold. This
suggests that other substitutions may further enhance the binding
affinity to FluA-PA and increases the antiviral activity of these
peptides. In one study, random substitutions of single aa within an
importin-alpha-binding peptide increased its affinity by several
orders of magnitude [45], providing proof of principle that the
development of potent peptide inhibitors from a peptide lead is
possible. The antiviral activity of VIRIP, a peptide that blocks
HIV-1 entry by interacting with the gp41 fusion peptide could be
increased in its antiretroviral potency by two orders of magnitude
[46]. Thus, random substitutions of the PA-binding domain may
Figure 5. Virus-type independent binding and inhibition of GFP fused to the dual binding peptide PB11–25AT6Y. (A) GFP-PB1 fusion
proteins used in (B). (B) Complex formation of PB11–25-derived GFP fusion proteins and HA-tagged PA of FluA and FluB. Indicated proteins were
expressed in human 293T cells and binding of the GFP fusion proteins was analyzed by IP using anti-HA agarose and subsequent immunoblotting.
Precipitated material was visualized using the indicated antibodies for the presence of either HA-tagged PA or GFP. Molecular weights are shown in
kilodaltons. (C) Polymerase inhibitory activity of PB11–25-derived GFP fusion proteins in FluA and FluB polymerase reconstitution assays. 293T cells were
transiently transfected with a plasmid mixture containing either Flu A (A/WSN/33) or Flu B (B/Yamagata/73) PB1-, PB2-, PA- and NP-expression plasmids,
polymerase I (Pol 1)-expressionplasmid expressing aninfluenzavirus-likeRNAcodingfor thereporter protein fireflyluciferase (FluA) or (FluB)to monitor
viral polymerase activity and expression plasmids coding for the indicated GFP fusion proteins. The transfection mixture also contained a plasmid
constitutivelyexpressing renilla luciferase (100 ng), whichservedtonormalizevariationin transfectionefficiency.Theactivity observed with transfection
reactions containing Flag-GFP were set to 100%. The omission of PB2 in the transfection mixture served as a negative control.
doi:10.1371/journal.pone.0007517.g005
Table 1. Peptides used for the plaque-reduction assay.
Peptide name Peptide sequence
PB11–25A-Tat MDVNPTLLFLKVPAQNAISTTFPYTYGRKKRRQRRRPP
PB11–25AT6Y-Tat MDVNPYLLFLKVPAQNAISTTFPYTYGRKKRRQRRRPP
PX-Tat LSNDELIKKLVTELAENSMIEAEEVYGRKKRRQRRRPP
The underlined Y highlights the tyrosine residue derived from the PB1 FluB sequence. Bold letters in italics represent the HIV-Tat derived sequence that allow the
peptides to cross the plasma membrane.
doi:10.1371/journal.pone.0007517.t001
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FluA-PA. This approach might also lead to the identification of
peptides, which bind PA of both virus types, using PB11–25A6Y as
the lead peptide. Most importantly, such peptides would be prime
candidates for the development of antiviral peptidomimetics.
Materials and Methods
Virus strains
Infection experiments were carried out using A/WSN/33
(H1N1) [32] and A/Thailand/1(Kan-1)/2004 [47], B/Yama-
gata/73 [48] and VSV (serotype Indiana) [49].
Plasmid constructions
Plasmids pCA-Flag-GFP and pCA-PB11–25A-GFP [32], pCA-
PB1-HA [32], the FluA minireplicon plasmids [50] and the
expression plasmids for the FluB minireplicon [32] were described
elsewhere. The FluB minigenome expression plasmid, pPolI-
lucRT_B, was obtained by cloning the firefly luciferase ORF
(inverse orientation) flanked bythenon-coding region ofthesegment
8 of the B/Yamagata/73 into the SapI-digested plasmid pPolI-SapI-
Rib [50]. For the construction of pCA-PB11–25B-GFP, a linker
containing the first 25 codons of PB1 (B/Yamagata/73) was cloned
into the EcoRI/NotI sites of pCA-Flag-GFP plasmid, replacing the
Flag-coding sequence with PB11–25B. Site directed mutagenesis was
carried out with pCA-PB11–25A-GFP to create the plasmid pCA-
PB11–25AT6Y-GFP. The ORFs of PB1 (B/Yamagata/73) and PA
(A/SC35M, A/Thailand/1(KAN-1)/04, A/Vietnam/1203/04, B/
Yamagata/73, B/Lee/40; accession numbers: Influenza A virus (A/
WSN/1933(H1N1))segment 2 (CY034138), segment 3 (CY034137),
A/SC35M(H7N7) segment 2 (DQ266098), segment 3 (DQ266099),
A/Thailand/1(KAN-1)/2004(H5N1) segment 3 (AY555150), B/
Lee/40 segment 3 (NC_002206)) were PCR amplified with sense
primers containing a NotI site (FluA strains) or a EcoRI site (FluB
strains)upstreamofthe initiation codon and antisenseprimers with a
deleted stop codon followed by an XmaI site, a coding sequence for
an HA-tag and a XhoI site. The PCR products were cloned into a
modified pCAGGs-vector [51] digested either with EcoRI/XhoI or
NotI/XhoI, resulting in pCA-PB1-HA or pCA-PA-HA plasmids,
coding for C-terminal tagged versions of the polymerase subunits.
To obtain the pCA-PAA/SC35M-His plasmid, pCA-PAA/SC35M-HA
was digested with XmaI/XhoI and the HA coding sequence was
replaced by a 6xHis-linker. The A/B-chimeric expression plasmids
wereobtainedbyassemblyPCR usingthe pCA-PB1-HA plasmidsof
SC35M and B/Yamagata/73 and by cloning the resulting PCR
productinpCA-PB1B/Yamagata/73-HA digested with EcoRI/EcoRV.
Reconstitution of the influenza virus polymerase activity
293T cells were transiently transfected with a plasmid mixture
containing either FluA- or FluB-derived PB1-, PB2-, PA- and NP-
expression plasmids, polymerase I (Pol I)-driven plasmid tran-
scribing an influenza A or influenza B virus-like RNA coding for
the reporter protein firefly luciferase to monitor viral polymerase
activity and with expression plasmids coding for the indicated GFP
Figure 6. Inhibition of FluA and FluB by the dual binding peptide PB11–25AT6Y. Plaque reduction assay using PB11–25A-Tat; PB11–25AT6Y-Tat;
PX-Tat (control peptide) [32] with FluA, FluB and VSV (vesicular stomatitis virus). A H2O control was used to standardize the assay to 100%. Note that
PB11–25B-Tat could not be tested due to insolubility. Error bars represent S.D.
doi:10.1371/journal.pone.0007517.g006
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coding sequences of segment 8 of FluA and FluB, respectively. The
transfection mixture also contained a plasmid constitutively
expressing Renilla luciferase, which served to normalize variation
in transfection efficiency. The reporter activity was determined
24 h post transfection and normalized using the Dual-GluH
Lufierase Assay System (Promega). The activity observed with
transfection reactions containing Flag-GFP were set to 100%.
Peptide synthesis
The solid-phase synthesis of the peptides, including the peptides
for the plaque reduction assay (Table 1), was carried out on a
Pioneer automatic peptide synthesizer (Applied Biosystems, Foster
City, USA) employing Fmoc chemistry with TBTU/diisopropy-
lethyl amine activation. Side chain protections were as follows:
Asp, Glu, Ser, Thr and Tyr: t-Bu; Asn, Gln and His: Trt; Arg: Pbf;
Lys and Trp: Boc. Coupling time was 1 h. Double couplings were
carried out if a difficult coupling was expected according to the
program Peptide Companion (CoshiSoft/PeptiSearch, Tucson,
USA). All peptides were generated as carboxyl amides by synthesis
on Rapp S RAM resin (Rapp Polymere, Tu ¨bingen, Germany).
Biotin was incorporated at the C-terminus of indicated peptides
with Fmoc-Lys(Biotin)-OH (NovaBiochem/Merck, Nottingham,
UK) and TBTU/diisopropylethyl amine activation for 18 h,
followed by coupling of Fmoc-b-Ala-OH for 1 h. Peptides were
cleaved from the resin and deprotected by a 3 h treatment with
TFA containing 3% triisobutylsilane and 2% water (10 ml/g
resin). After precipitation with t-butylmethyl ether, the resulting
crude peptides were purified by preparative HPLC (RP-18) with
water/acetonitrile gradients containing 0.1% TFA and character-
ized by analytical HPLC and MALDI-MS. Some peptides were
synthesized by peptides&elephants (Nuthetal, Germany) and
subsequently purified and characterized as described above.
Immunoprecipitation experiments
293T cells were transfected with the indicated plasmids in 6-well
plates using Metafectene (Biontex, Martinsried, Germany). Cells
were incubated 24 h post transfection with lysis buffer (20 mM
Tris pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1%
Protease inhibitor Mix G, (Serva, Heidelberg, Germany), 1 mM
DTT) for 15 min on ice. After centrifugation by 13.000 rpm at
4uC supernatant was incubated with anti HA-specific antibodies
coupled to agarose beads (Sigma) for 1 h at 4uC. After three
washes with 1 ml of washing buffer (lysis buffer without protease
inhibitor mix), bound material was eluted under denaturing
conditions and separated on SDS-PAGE gels and transferred to
PVDF membranes. Viral polymerase subunits and GFP fusion
proteins were detected with antibodies directed against the HA-
(Covance, Berkeley, California) or His-(Qiagen) or GFP-tag (Santa
Cruz Biotechnology).
Plaque reduction assay. The experiments were carried out
as described [52] with modifications. Confluent MDCK cells were
infected with 80 PFU of A/WSN/33, B/Yamagata/73, A/KAN-
1, or VSV/Indiana in PBS at room temperature. After removal of
the inoculums, cells were overlaid with medium (DMEM with
20 mM Hepes) containing 1% Oxoidagar and peptides at the
indicated concentrations. After incubation for 24 h (VSV), 48 h (A/
WSN/33, A/KAN-1) at 37uC with 5% CO2, or 72 h at 33uC with
5% CO2 (B/Yamagata/73) respectively, cells were fixed with
formaldehyde and stained with crystal violet. Plaques were counted
and mean plaque number of the water control was set to 100%.
ELISA
Streptavidin-coated microwell plates were incubated with
saturating concentrations of biotinylated peptides, washed and
subsequently incubated at room temperature with HA-tagged PA.
To obtain PA-HA, 293T cells were seeded into 94 mm-dishes,
transfected with the respective plasmid and treated with lysis buffer
24 h post transfection as previously described [32]. After washing
the microwell plates, the wells were incubated with an HA-specific
primary antibody (Covance, MMS-101R), followed by three
washes and an incubation with a peroxidase-coupled secondary
antibody (Jackson Immuno Research, Newmarket, UK). After the
final wash step, ABTS-substrate (Sigma, ready-to-use solution) was
added and the optical density was determined at 405 nm.
The competition ELISA was carried out as described above
with the exception that the competitor peptides were added to
wells of the plate with bound peptides simultaneously with the
addition of the cell extract containing HA-tagged PA subunits.
Sequence alignment. Alignments were performed with
MUSCLE [53] using the full-length sequences provided from
the public influenza virus database (http://www.ncbi.nlm.nih.
gov/genomes/FLU/FLU.html).
Modeling. Manual docking of the mutated peptide into the
PA(C)-PB1(N) crystal structure [25] and subsequent minimization
was performed with Accelrys Discovery Studio.
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